Who are labetalol intravenous's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Experimental dosing of labetalol, ephedrine and phenylephrine, Epinephrine Injection, Labetalol, Nifedipine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/labetalol-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

labetalol intravenous — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

labetalol intravenous (labetalol intravenous) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-beta adrenergic antagonist. Area: Cardiovascular.

marketed Alpha-beta adrenergic antagonist Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

labetalol intravenous (labetalol intravenous) — Haseki Training and Research Hospital. Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking sympathetic nervous system signaling.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
labetalol intravenous TARGET	labetalol intravenous	Haseki Training and Research Hospital	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Experimental dosing of labetalol	Experimental dosing of labetalol	Albany Medical College	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
ephedrine and phenylephrine	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor
Epinephrine Injection	Epinephrine Injection	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	marketed	Catecholamine; alpha and beta adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Labetalol, Nifedipine	Labetalol, Nifedipine	Medical College of Wisconsin	phase 3	Combination antihypertensive (beta-blocker + calcium channel blocker)	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-beta adrenergic antagonist class)

Albany Medical College · 1 drug in this class
Haseki Training and Research Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). labetalol intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/labetalol-intravenous. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab